Zydus Lifesciences shines on getting USFDA`s approval for ZITUVIO tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Zydus Lifesciences is currently trading at Rs. 581.10, up by 2.55 points or 0.44% from its previous closing of Rs. 578.55 on the BSE.
The scrip opened at Rs. 578.60 and has touched a high and low of Rs. 589.15 and Rs. 578.60 respectively. So far 2305 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 390.10 on 22-Nov-2022.
Last one week high and low of the scrip stood at Rs. 597.30 and Rs. 573.80 respectively. The current market cap of the company is Rs. 58561.07 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.95% and 7.07% respectively.
Zydus Lifesciences has received approval from the United States Food and Drug Administration (USFDA) for its New Drug Application (NDA) for ZITUVIO (Sitagliptin) tablets, 25 mg, 50 mg, and 100 mg. ZITUVIO contains active ingredient Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
The approval of ZITUVIO is based on research, development, regulatory and manufacturing work performed by Zydus teams. ZITUVIO has undergone quality testing for Nitrosamines and potential genotoxic impurities as per current USFDA standards. ZITUVIO is compliant with current USFDA standards of Nitrosamines in Sitagliptin containing products. According to IQVIA (MAT August 2023), U.S. market for DPP-IV inhibitors and its combinations is $10 billion.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
